(Q37226372)

19 August 2017

1 reference

title

The effects of pharmacologic agents for type 2 diabetes mellitus on body weight (English)

1 reference

19 August 2017

0 references

1 reference

F Xavier Pi-Sunyer

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

19 August 2017

published in

Postgraduate Medicine

1 reference

19 August 2017

volume

120

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

5-17

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Obesity: new perspectives and pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Paul Zimmet: fighting the "diabesity" pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Obesity and diabetes in the developing world--a growing challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The perils of portliness: causes and consequences of visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Economic costs of diabetes in the US in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Relationship of metabolic risk factors and development of cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Does the predictive value of baseline coronary risk factors change over a 30-year follow-up?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Drugs on the horizon for diabesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of comorbid chronic diseases on prevalence and odds of depression in adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The prevalence of comorbid depression in adults with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The obese hypertensive: the weight of evidence against beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The U.K. Prospective Diabetes Study. A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Differentiating members of the thiazolidinedione class: a focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Intensive insulin therapy and weight gain in IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Does insulin detemir have a role in reducing risk of insulin-associated weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effects of orlistat on obesity-related diseases - a six-month randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Thermogenic effects of sibutramine and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Experience with the Roux-en-Y gastric bypass, and commentary on current trends

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Long-term mortality after gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Glycemic control in diabetic patients after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Prevention of Obesity and Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

How many cases of Type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the Midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.07.1785

21 January 2018

Identifiers

DOI

10.3810/PGM.2008.07.1785

1 reference

release_tsrjng3hkvbipdqcrkeb4wtknm

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tsrjng3hkvbipdqcrkeb4wtknm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference